Abstract:1155 Objectives Prostate specific membrane antigen (PSMA) is a membrane bound glycoprotein that is overexpressed on the cell surface of prostate cancer cells. A few PSMA-targeting radiotracers have been successfully introduced in clinical studies for imaging prostate cancer by PET. 18F-DCFPyL is currently the most sensitive tracer for the identification of PSMA-positive prostate cancer. However, the procedure for producing 18F-DCFPyL involves multiple synthesis steps. In this study, two 18F-labeled PSMA-targeting tracers (HTK-01069 and HTK-01070) that could be radiolabeled via 18F-19F isotope exchange on the ammoniomethyl-trifluoroborate (AmBF3) motif were synthesized and evaluated for PSMA imaging. Methods HTK-01069 was synthesized by coupling succinimido 4-(N-trifluoroborylmethyl-N,N-dimethylammonio)methylbenzoate to Lys-C(O)-Glu urea. HTK-01070 was prepared by coupling tetrafluorophenyl 4-(azidemethyl)benzoate to t-butyl protected Lys-C(O)-Glu urea, followed by deprotection and click reaction with N-propargyl-N,N-dimethyl-ammoniomethyltrifluoroborate. 18F-19F isotope exchange reactions were conducted for radiolabeling and both tracers were purified by HPLC. The stability of the tracers was assessed in mouse plasma for 2 h and LogD7.4 values were determined by the shake-flask method. PET imaging and biodistribution studies were performed in mice bearing PSMA-expressing LNCap prostate cancer xenografts. For blocking studies, mice were co-injected with 0.5 mg of DCFPyL. Results 18F-HTK-01069 and 18F-HTK-01070 were obtained in 9% and 3% decay-corrected radiochemical yields with > 99% radiochemical purity. The specific activities for 18F-HTK-01069 and 18F-HTK-01070 were 2.0 and 1.3 Ci/μmol, respectively. Both tracers were stable after 2 h incubation in plasma and were highly hydrophilic with LogD7.4 values between -3.4 and -4.3. From the PET and biodistribution data, 18F-HTK-01069 and 18F-HTK-01070 demonstrated clear PSMA-dependent uptake in LNCap prostate cancer xenografts at 1 h post-injection (p.i.). The clearance of both 18F-HTK-01069 and 18F-HTK-01070 was predominantly renal with minor involvement of the hepatobiliary pathway. At 1 h p.i., 18F-HTK-01070 exhibited higher tumour uptake (8.28 ± 1.25 %ID/g) than 18F-HTK-01069 (5.82 ± 1.09 %ID/g). 18F-HTK-01070 was also superior to 18F-HTK-01069 in terms of tumour-to-muscle ratio (37.7 ± 9.53 vs. 18.9 ± 6.05) and tumour-to-blood ratio (16.0 ± 1.37 vs. 11.9 ± 4.60). With PSMA blockade, uptake in tumours decreased significantly to 0.33 ± 0.07 and 0.27 ± 0.06 %ID/g for 18F-HTK-01069 and 18F-HTK-01070, respectively. Conclusions Two novel imaging agents, 18F-HTK-01069 and 18F-HTK-01070, were synthesized and evaluated for targeting PSMA expression with PET. Administration of 18F-HTK-01069 or 18F-HTK-01070 allowed for clear visualization of LNCap tumours in mice, with 18F-HTK-01070 yielding higher uptake and contrast. The data suggests that 18F-AmBF3-PSMA derivatives are promising agents for detecting PSMA-expressing prostate cancers.

Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression

Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1)

Novel 18F-Labeled Isonicotinamide-Based Radioligands for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3β

Synthesis and Evaluation of Two Novel 2-Nitroimidazole Derivatives As Potential Pet Radioligands for Tumor Imaging

Preclinical and exploratory human studies of novel 68 Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers

Synthesis and Biological Evaluation of Novel F-18 Labeled Pyrazolo[1,5-A]pyrimidine Derivatives: Potential PET Imaging Agents for Tumor Detection.

RADI-17. EVALUATION OF A NOVEL 18F-LABELED TRYPTOPHAN TRACER FOR PET IMAGING OF BRAIN TUMORS IN A MEDULLOBLASTOMA MOUSE MODEL

Synthesis of 5-[18F]fluoro-α-methyl Tryptophan: New Trp Based PET Agents.

In Vivo Ester Hydrolysis As a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.

Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease

Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging.

Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers

18F-HX4/18F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice

Discovery and Evaluation of Imidazo[2,1- b][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging

Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers.

Synthesis and Evaluation Of111in-Dota-mab109 Monoclonal Antibody for Potential SPECT Molecular Imaging

Synthesis and Evaluation of F-18-Ambf3-Psma Derivatives As Pet Imaging Agents for Prostate Cancer

Synthesis and Evaluation of Novel F-18 Labeled Fluoroarylvaline Derivatives: Potential Pet Imaging Agents for Tumor Detection

Development of [18F]DASA-23 for Imaging Tumor Glycolysis Through Noninvasive Measurement of Pyruvate Kinase M2

18F-labeled Pyrazolo[1,5-a]pyrimidine Derivatives: Synthesis from 2,4-Dinitrobenzamide and Tosylate Precursors and Comparative Biological Evaluation for Tumor Imaging with Positron Emission Tomography

Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-butyl-2-(4-(2-[18f]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-n,n-diethylacetamide (18F-VUIIS1018A) to Image Glioma.